Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Continued Good News From Mayo Clinic Pomalidomide (CC4047) Studies

Home/Continued Good News From Mayo Clinic Pomalidomide (CC4047) Studies

Continued Good News From Mayo Clinic Pomalidomide (CC4047) Studies

This is very good news as posted on OncologySTAT yesterday:

Pomalidomide (CC4047) Plus Low Dose Dexamethasone (Pom/dex) is Active and Well Tolerated In Lenalidomide Refractory Multiple Myeloma (MM)
Leukemia. 2010 Nov 1;24(11):1934-1939, MQ Lacy, SR Hayman, MA Gertz, KD Short, A Dispenzieri, S Kumar, PR Greipp, JA Lust, SJ Russell, D Dingli, S Zeldenrust, R Fonseca, PL Bergsagel, V Roy, JR Mikhael, AD Stewart, K Laumann, JB Allred, SJ Mandrekar, SV Rajkumar, F Buadi
Results of this phase II trial enrolling 34 heavily-pretreated patients with multiple myeloma that was refractory to lenalidomide showed that the combination of pomalidomide plus dexamethasone was highly…
TAKE-HOME MESSAGE
Results of this phase II trial enrolling 34 heavily-pretreated patients with multiple myeloma that was refractory to lenalidomide showed that the combination of pomalidomide plus dexamethasone was highly active and well tolerated.

Abstract
Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and previous studies suggest activity in lenalidomide refractory disease. To better define its efficacy in this group, we treated a cohort of lenalidomide refractory patients. Pomalidomide was given orally (2 mg) daily, continuously in 28-day cycles along with dexamethasone (40 mg) given weekly. Responses were assessed by the International Myeloma Working Group Criteria. Thirty-four patients were enrolled. The best response was very good partial response in 3 (9%), partial response (PR) in 8 (23%), best responses (MR) in 5 (15%), stable disease in 12 (35%) and progressive disease in 6 (18%), for an overall response rate of 47%. Of the 14 patients that were considered high risk, 8 (57%) had responses including 4 PR and 4 MR. The median time to response was 2 months and response duration was 9.1 months, respectively. The median overall survival was 13.9 months. Toxicity was primarily hematologic, with grade 3 or 4 toxicity seen in 18 patients (53%) consisting of anemia (12%), thrombocytopenia (9%) and neutropenia (26%). The combination of pomalidomide and dexamethasone (Pom/dex) is highly active and well tolerated in patients with lenalidomide-refractory myeloma.

Lenalidomide is, of course, Revlimid. It is always good news when a drug’s analogue, or second generation, works in patients who became refractory to the original drug. This means there is just enough difference between pomalidomide and Revlimid to give relapsed patients who were using Revlimid hope. Not perfect at 47%, but pretty cool none the less.

Feel good and keep smiling! Pat